The Food and Drug Administration has licensed Ezplaz Freeze Dried Plasma, the first freeze-dried plasma product approved for use in the U.S.
Ezplaz is intended for adult patients who require plasma when conventional plasma products are unavailable. Potential uses include treating patients with severe bleeding, supporting massive transfusion protocols, and treating certain patients taking warfarin who are experiencing bleeding.
Unlike conventional plasma, which requires frozen storage and thawing before transfusion, Ezplaz can be stored at room temperature, withstand temperature fluctuations, and be rapidly reconstituted. The product is packaged in a plastic bag to reduce the risk of breakage during storage, handling, and transportation.
Each self-contained kit includes one unit of freeze-dried plasma, sterile water for injection, a fluid transfer set, and a blood transfusion set. Ezplaz is available as Group AB plasma and Group A plasma with low-titer anti-B antibodies, allowing it to be used in emergencies before a patient’s blood type is known.
The FDA said these features could improve plasma availability in combat zones, disaster-response operations, rural communities, and other environments located far from traditional hospital infrastructure. The agency awarded the biologics license to Vascular Solutions, a Teleflex subsidiary.
Why it matters for healthcare operations
The product introduces a new option for organizations that have difficulty maintaining frozen-plasma inventories or quickly thawing plasma. Hospitals and health systems may need to assess how Ezplaz could fit into emergency preparedness plans, massive transfusion protocols, and supply strategies for rural facilities, ambulances, air-medical programs, and disaster-response teams.
Supply chain, pharmacy, laboratory, blood bank, and clinical leaders would also need to coordinate purchasing, storage, staff training, inventory rotation, and transfusion procedures before incorporating the product into practice. The FDA noted that Ezplaz carries risks consistent with other plasma transfusions and that providers should review its prescribing information before use.
